- Home
- ONMD vs PHGE Comparison
ONMD vs PHGE Comparison
Compare ONMD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- PHGE
- Stock Information
- Founded
- ONMD 2006
- PHGE 2015
- Country
- ONMD United States
- PHGE Israel
- Employees
- ONMD N/A
- PHGE N/A
- Industry
- ONMD
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ONMD
- PHGE Health Care
- Exchange
- ONMD Nasdaq
- PHGE Nasdaq
- Market Cap
- ONMD 23.9M
- PHGE 26.5M
- IPO Year
- ONMD N/A
- PHGE N/A
- Fundamental
- Price
- ONMD $0.84
- PHGE $0.49
- Analyst Decision
- ONMD
- PHGE Strong Buy
- Analyst Count
- ONMD 0
- PHGE 2
- Target Price
- ONMD N/A
- PHGE $22.50
- AVG Volume (30 Days)
- ONMD 498.5K
- PHGE 159.9K
- Earning Date
- ONMD 12-03-2024
- PHGE 11-14-2024
- Dividend Yield
- ONMD N/A
- PHGE N/A
- EPS Growth
- ONMD N/A
- PHGE N/A
- EPS
- ONMD N/A
- PHGE N/A
- Revenue
- ONMD $1,021,651.00
- PHGE N/A
- Revenue This Year
- ONMD N/A
- PHGE N/A
- Revenue Next Year
- ONMD N/A
- PHGE N/A
- P/E Ratio
- ONMD N/A
- PHGE N/A
- Revenue Growth
- ONMD N/A
- PHGE N/A
- 52 Week Low
- ONMD $0.42
- PHGE $0.49
- 52 Week High
- ONMD $4.43
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- ONMD 52.31
- PHGE 21.78
- Support Level
- ONMD $0.81
- PHGE $0.56
- Resistance Level
- ONMD $0.87
- PHGE $0.79
- Average True Range (ATR)
- ONMD 0.13
- PHGE 0.10
- MACD
- ONMD -0.00
- PHGE -0.02
- Stochastic Oscillator
- ONMD 53.27
- PHGE 0.00
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.